Sugi Predict

Sugi Predict / Compounds / SCHEMBL897447

SCHEMBL897447

SCHEMBL897447

COc1ccc2c(c1)Cc1c([nH]c3cccc(C#N)c13)C2(C)C

nearest known ligand 0.43

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 3/20 0.43
▸ CA2 P00918 3/20 0.43
▸ CA4 P22748 3/20 0.43
▸ CA6 P23280 3/20 0.43
▸ ALK Q9UM73 7/20 0.40
▸ DRD2 P14416 4/20 0.38
▸ DRD1 P21728 4/20 0.38
▸ DRD5 P21918 4/20 0.38
▸ DRD3 P35462 4/20 0.38
▸ SRC P12931 2/20 0.35
▸ GAA P10253 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ GLA P06280 1/20 0.35
▸ L3MBTL1 Q9Y468 1/20 0.35
▸ POLB P06746 1/20 0.33
▸ DRD4 P21917 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23027947 0.85 CA1 (0.45) CA1CA2CA4CA6DRD2
SCHEMBL898146 0.82 ALK (0.43) CA1CA2CA4CA6ALK
SCHEMBL897479 0.82 CLK1 (0.35) CA1CA2CA4CA6ALK
SCHEMBL31548017 0.82 ALK (0.43) CA1CA2CA4CA6ALK
SCHEMBL21613391 0.81 CA1 (0.40) CA1CA2CA4CA6DRD2
SCHEMBL897691 0.78 ALK (0.50) ALK
SCHEMBL896681 0.76 CA1 (0.43) CA1CA2CA4CA6DRD2
SCHEMBL15061898 0.73 CA1 (0.39) CA1CA2CA4CA6ALK
SCHEMBL1755993 0.71 CA1 (0.48) CA1CA2CA4CA6ALK
SCHEMBL897520 0.70 ALK (0.52) CA1CA2CA4CA6ALK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114327-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-04-10 — — US disclosed
US-20230398096-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-12-14 — — US disclosed
US-20230398096-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-12-14 — — US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20230142119-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-11 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
US-20220306578-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2022-09-29 — — US disclosed
US-20210052550-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-02-25 — — US disclosed
US-20210052550-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-02-25 — — US disclosed
EP-3698788-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-08-26 — — EP disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 — — US disclosed
US-9126931-B2 Tetracyclic compound CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-09-08 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
US-20150150845-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-06-04 — — US disclosed
EP-2606886-A1 COMPOSITION CONTAINING TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2013-06-26 — — EP disclosed
US-20130143877-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-06-06 — — US disclosed
US-20130143877-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2013-06-06 — — US disclosed
EP-2441753-A1 TETRACYCLIC COMPOUND Chugai Seiyaku Kabushiki Kaisha (JP) 2012-04-18 — — EP disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed
US-20120083488-A1 TETRACYCLIC COMPOUND CHUGAI SEIYAKU KABUSHIKI KAISHA 2012-04-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130143877-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR CA1 102/4885CA2 940/4885CA4 462/4885
US-20230142119-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CA1 50/4885CA2 291/4885CA4 254/4885
US-20250114327-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR CA1 102/4885CA2 940/4885CA4 462/4885
US-20120083488-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CA1 50/4885CA2 291/4885CA4 254/4885
US-20220306578-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CA1 50/4885CA2 291/4885CA4 254/4885
US-20230398096-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR CA1 102/4885CA2 940/4885CA4 462/4885
US-20210052550-A1 COMPOSITION COMPRISING TETRACYCLIC COMPOUND ALK, ALPI, TTR CA1 102/4885CA2 940/4885CA4 462/4885
US-20150150845-A1 TETRACYCLIC COMPOUND ALK, TTR, ACVR1 CA1 50/4885CA2 291/4885CA4 254/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.